DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 retatrutide - 2 Lilly - 2 Lilly's - 2 Evan David Seigerman - 2 It's - 1 Eli Lilly's - 1 there's - 1
Top related locs:
Novo San Diego Denmark GLP It's Novo Nordisk's Branchburg , New Jersey
Top related orgs:
Novo Nordisk - 2 American Diabetes Association - 2 Barclays - 2 JPMorgan - 2 BMO Capital - 2 Club - 1 New England - 1 of Medicine - 1

Search resuls for: "Evan David Seigerman"


7 mentions found


☆ Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic
  + stars: | 2023-06-28 | by ( Kevin Stankiewicz | In Kevinstankiewicz | ) www.cnbc.com   time to read: +10 min
The company's chief rival, Denmark-based Novo Nordisk (NVO), also published promising data on drugs in its pipeline, including its own oral weight-loss treatment. Other pharmaceutical companies are racing to compete with Novo Nordisk and Eli Lilly, including Amgen (AMGN) and Pfizer (PFE). Barclays on Tuesday projected Eli Lilly's three leading obesity-and-diabetes drugs could generate nearly $49 billion in combined sales in 2030. Eli Lilly Eli Lilly has multiple drugs in development that fall under the GLP-1 umbrella in various stages of clinical development. Novo Nordisk Novo Nordisk currently dominates the market for GLP-1 drugs, with three products in the class on the U.S. market already: Ozempic, Wegovy and Rybelsus.
Persons: It's, Eli Lilly, Eli Lilly's, retatrutide, Lilly, there's, Lilly's, Geoff Meacham, Eli Lilly Eli Lilly, Jim Cramer, Evan David Seigerman, —, — Morgan Stanley, Wegovy, Rybelsus, Jim Cramer's, Jim, Mike Segar Organizations: Club, Novo Nordisk, New England, of Medicine, American Diabetes Association, Pfizer, Reuters, Barclays, Bank of America, CNBC, JPMorgan, Drug Administration, Equity, BMO Capital, Novo Nordisk Novo Nordisk, GLP, FDA, Nordisk, Company Locations: San Diego, Denmark, GLP, It's, Novo, Novo Nordisk's, Branchburg , New Jersey
☆ Eli Lilly's weight loss drugs trounce sky-high expectations, boosting the stock
  + stars: | 2023-06-27 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +5 min
What's more, some showed no signs their weight loss was leveling off, suggesting they could continue to shed pounds. (Both use semaglutide, but Ozempic is marketed as a type 2 diabetes treatment, while Wegovy is primarily for weight loss.) Bank of America's Geoff Meacham said retatrutide "exceeded expectations" for weight loss. "This is important, as while the overall 22.4% weight loss was impressive, looking at men and women separately, weight loss was 21.9% and 28.5%, respectively, with the slope in females not yet plateauing. Schott also described the weight loss as "impressive" and said it will likely compare favorably with Novo's next-generation drug CagriSema, which is expected to show weight loss of more than 25% when it releases its next update.
Persons: Eli Lilly, What's, Lilly, Lilly's, Carter Gould, Gould, orforglipron, Bank of America's Geoff Meacham, retatrutide, Meacham, Chris Schott, Schott, Novo's, Evan David Seigerman, Seigerman, Morgan Stanley, Terence Flynn, — CNBC's Michael Bloom Organizations: American Diabetes Association, Wall, Novo Nordisk, Barclays, Bank of America's, JPMorgan, Lilly, BMO Capital, Indianapolis, ~$ Locations: Novo
☆ BMO Capital Markets says this biotech company is 'best-in-class,' sees shares surging more than 25%
  + stars: | 2023-05-16 | by ( Hakyung Kim | Https | Www.Linkedin.Com In Hakyungkim | ) www.cnbc.com   time to read: +1 min
BMO Capital Markets says Gilead Sciences is a "best-in-class" therapy franchise that could soon see multiple expansion. The firm upgraded shares to outperform from market perform and raised its price target to $100 from $90. The new price target implies shares rallying 27.5% from Monday's close. Analyst Evan David Seigerman said that, in addition to Gilead's strong therapy franchise, its improving solid tumor oncology business and durable-growth anchored by its HIV/virology division could lead to strong growth. "While we note that Gilead currently trades at a discount to large-cap peers, continued de-risking of its oncology franchise could drive multiple expansion."
☆ Positive Alzheimer's drug trial data pushes Eli Lilly shares to another all-time high and brightens our outlook
  + stars: | 2023-05-03 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +7 min
LLY 1Y mountain Shares of Eli Lilly over the past 12 months. The FDA granted accelerated approval to an anti-amyloid drug — developed by Japanese pharmaceutical firm Eisai and U.S.-based partner Biogen (BIIB) — in early January. For Eli Lilly, specifically, Seigerman said the donanemab data appears to be a "home run." Eli Lilly said two participants in the Phase 3 trial died due to ARIA side effects, while a third patient did after a serious ARIA incident. The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
☆ This little-known biotech stock developing treatments for blood disorders could jump 80%, BMO says
  + stars: | 2023-03-23 | by ( Sarah Min | ) www.cnbc.com   time to read: +2 min
Investors should take a closer look at Disc Medicine as it develops treatments for blood disorders, according to BMO Capital Markets. Analyst Evan David Seigerman initiated coverage of Disc Medicine with an outperform rating and a $40 price target, saying that the firm's development of bitopertin to treat erythropoietic porphyrias and other blood disorders appears promising. IRON YTD mountain Disc Medicine shares YTD Last year, Disc Medicine went public in a reverse merger with biotechnology company Gemini Therapeutics, trading under the ticker symbol "IRON." Disc Medicine shares are up 8% this year. The analyst's $40 price target means that Disc Medicine shares can jump 84% from Wednesday's closing price.
☆ This biotech startup has a chance to grab a piece of the lucrative obesity drug market, analysts say
  + stars: | 2023-02-28 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +3 min
Enter biotech startup Structure Therapeutics , which is hoping to change that regimen with oral GLP-1 formulations for obesity and type 2 diabetes treatment. The stock rallied 73% in its first day of trading, but has pulled back in the weeks since its debut. Novo Nordisk's Wegovy and Ozempic are currently on the market and approved to treat obesity and type 2 diabetes. BMO was among the group of investment banks acting as joint book runners for Structure's IPO. (Jefferies was the lead book runner in Structure's IPO.)
☆ Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly
  + stars: | 2022-09-28 | by ( Kevin Stankiewicz | ) www.cnbc.com   time to read: +8 min
The move helped Eli Lilly notch a fresh 52-week high Wednesday, the only stock in the S & P 500 to do so. Bottom line Biogen's topline data appears to be encouraging, suggesting the Alzheimer's drug helped slowed cognitive decline. Plus, we think Eli Lilly has more going for it overall than Biogen, making it a more attractive investment. Drug background Like Biogen's Alzheimer's drug lecanemab, Lilly's donanemab is an antibody that tries to reduce buildup on the brain of the amyloid beta protein . The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.
0 next >>
Total: 7